KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Castle Biosciences (CSTL) Shares Outstanding (Weighted Average) (2018 - 2025)

Historic Shares Outstanding (Weighted Average) for Castle Biosciences (CSTL) over the last 8 years, with Q3 2025 value amounting to $29.1 million.

  • Castle Biosciences' Shares Outstanding (Weighted Average) rose 442.89% to $29.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $29.1 million, marking a year-over-year increase of 442.89%. This contributed to the annual value of $27.8 million for FY2024, which is 363.41% up from last year.
  • According to the latest figures from Q3 2025, Castle Biosciences' Shares Outstanding (Weighted Average) is $29.1 million, which was up 442.89% from $28.9 million recorded in Q2 2025.
  • Castle Biosciences' Shares Outstanding (Weighted Average)'s 5-year high stood at $29.1 million during Q3 2025, with a 5-year trough of $24.9 million in Q1 2021.
  • In the last 5 years, Castle Biosciences' Shares Outstanding (Weighted Average) had a median value of $26.7 million in 2023 and averaged $26.8 million.
  • Its Shares Outstanding (Weighted Average) has fluctuated over the past 5 years, first soared by 4340.32% in 2021, then surged by 196.84% in 2023.
  • Castle Biosciences' Shares Outstanding (Weighted Average) (Quarter) stood at $25.1 million in 2021, then increased by 3.65% to $26.1 million in 2022, then increased by 2.87% to $26.8 million in 2023, then grew by 3.63% to $27.8 million in 2024, then rose by 4.67% to $29.1 million in 2025.
  • Its last three reported values are $29.1 million in Q3 2025, $28.9 million for Q2 2025, and $28.6 million during Q1 2025.